Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Management of angiosarcoma.

G Thomas Budd1

  • 1Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, R35, 9500 Euclid Avenue, Cleveland, OH 44195, USA. buddg@ccf.org

Current Oncology Reports
|October 2, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Time-course based assessment of patient factors and their relationship to chemotherapy induced peripheral neuropathy.

Frontiers in pain research (Lausanne, Switzerland)·2026
Same author

Longitudinal multi-omics analyses of chemotherapy-induced peripheral neuropathy in response to taxanes.

BMC cancer·2025
Same author

A Chemotherapy Responsive Ewing Sarcoma Case Report With a Rare FUS::FLI1 Fusion.

Case reports in pathology·2025
Same author

Adjunctive statistical standardization of quantitated adjuvant HER2 and ultra-low HER2 in Canadian Cancer Trials Group MA.27 trial of exemestane versus anastrozole.

Breast cancer research and treatment·2025
Same author

Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer.

Breast cancer research and treatment·2024
Same author

Adjunctive Statistical Standardization of Adjuvant Estrogen Receptor and Progesterone Receptor in Canadian Cancer Trials Group MA.27 Postmenopausal Breast Cancer Trial of Exemestane Versus Anastrozole.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2024
Same journal

Revisiting the Immunological Landscape of Locoregional Therapies for Gastrointestinal Cancers: A Shift Toward Interventional Immuno-Oncology.

Current oncology reports·2026
Same journal

Anti-PD-1 Combinations: Triplets and Beyond.

Current oncology reports·2026
Same journal

Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases.

Current oncology reports·2026
Same journal

Clusterin in Head and Neck Squamous Cell Carcinoma: Diagnostic, Prognostic, and Therapeutic Implications.

Current oncology reports·2026
Same journal

Cardiac Risk Without a Roadmap: Lack of Evidence-Based Guidance for Cardiovascular Toxicity of T-Cell Redirecting Therapies.

Current oncology reports·2026
Same journal

Current Understanding of CHIP's Immunobiological Footprint with A Focus on Gastrointestinal Disorders: A Review of the Literature.

Current oncology reports·2026
See all related articles

Angiosarcoma, a rare vascular cancer, presents challenges due to its widespread nature and aggressive growth. New antiangiogenic therapies are needed to improve treatment outcomes for this difficult-to-control cancer.

Area of Science:

  • Oncology
  • Vascular Biology
  • Cancer Therapeutics

Background:

  • Angiosarcoma is a rare vascular tumor with diverse presentations, often multifocal and locally invasive.
  • Common sites include the face/scalp, areas with chronic lymphedema, post-radiotherapy sites, and the liver.
  • Current treatments like doxorubicin-ifosfamide chemotherapy and paclitaxel offer limited efficacy, highlighting the need for improved systemic therapies.

Purpose of the Study:

  • To review the clinical presentation, challenges, and current therapeutic landscape of angiosarcoma.
  • To identify areas for future research and therapeutic development, particularly focusing on antiangiogenic strategies.

Main Methods:

  • Literature review of angiosarcoma presentations and treatment outcomes.
  • Analysis of current chemotherapy regimens and their response rates.

Related Experiment Videos

  • Discussion of potential novel therapeutic targets based on tumor biology.

    • Main Results:

    • Angiosarcoma is characterized by multifocality and insidious growth, complicating local control.
    • Chemotherapy with doxorubicin-ifosfamide shows modest response rates.
    • Paclitaxel demonstrates utility in specific angiosarcoma subtypes (scalp/facial).

    Conclusions:

    • Significant unmet need exists for more effective systemic therapies for angiosarcoma.
    • Antiangiogenic therapies represent a promising avenue for investigation in this endothelial tumor.
    • Further understanding of angiosarcoma biology is crucial for developing improved treatments.